Do You Have an Elevated Risk for Opioid Addiction?
Opioid addiction can impact anyone, but some people are at higher risk than others. Are you one of them? If your doctor is considering prescribing opioids to treat your acute pain (pain expected to last less than 30 days), AvertD can help you make more informed decisions by better understanding your genetic risk for opioid addiction before a prescription is written.
Do You Have an Elevated Risk for Opioid Addiction?
Opioid addiction can impact anyone, but some people are at higher risk than others. Are you one of them? If your doctor is considering prescribing opioids to treat your acute pain (pain expected to last less than 30 days), AvertD can help you make more informed decisions by better understanding your genetic risk for opioid addiction before a prescription is written.
Know Your Genetic Risk
for Opioid Use Disorder
Opioid medications are effective for treating acute pain―pain expected to last less than 30 days―but they also come with a risk of addiction. For some people, that risk is higher than others. Who is at increased risk? Some of the answer is found in our DNA.
In fact, the genes you carry are an important factor that influences whether you are at increased risk for opioid addiction (also called Opioid Use Disorder, or OUD).1 Now, thanks to AvertD™, patients and their healthcare providers have a way to identify if they may have an elevated genetic risk for OUD before a first prescription is written.
Make More Informed
Decisions with AvertD
AvertD is a simple genetic test that requires only a painless cheek swab. It analyzes DNA markers associated with opioid addiction and tells you if your genetic risk for addiction is elevated or not. Having this personalized risk information allows you and your doctor to make more informed decisions about whether the use of prescription oral opioids to treat acute pain is appropriate for you.
NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.
Make More Informed
Decisions with AvertD
AvertD is a simple genetic test that requires only a painless cheek swab. It analyzes DNA markers associated with opioid addiction and tells you if you may have an elevated genetic risk for OUD. Having this personalized risk information allows you and your doctor to make more informed decisions about whether the use of prescription oral opioids to treat acute pain is appropriate for you.
NOTE: Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.
AvertD is Simple
& Easy to Use
01
When a first prescription for oral opioids to treat acute pain is being considered, ask your healthcare provider to order the AvertD test.
02
Your provider will receive your test results via a secure online portal after your sample is received and processed at our CAP-accredited and CLIA-certified lab.
03
You and your healthcare provider will review your test results, discuss your pain management options, and create a plan together.
Find Out If Prescription Opioids
Are Appropriate for You
If you are identified as having an Elevated Genetic Risk, you and your doctor may wish to explore alternative pain management options in order to minimize or avoid use of oral opioids if medically appropriate. It’s important to note that an Elevated Genetic Risk result does not mean you have or will develop OUD. However, it does mean your risk of developing OUD is ~18 times higher than those with a Non-Elevated Genetic Risk.2
If you are identified as having a Non-Elevated Genetic Risk, you and your doctor should still follow existing medical guidelines to ensure safe and effective opioid prescribing. It’s important to note that a Non-Elevated Genetic Risk result does not mean you do not have or will not develop OUD. However, your risk of developing OUD is ~18 times lower than those with an Elevated Genetic Risk. 2
What AvertD Testing Costs
Our goal is to offer the lowest cost option available to you. We are working diligently to ensure AvertD is covered by most insurance companies. Depending on your insurance, your maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on your behalf. Please check with your insurance company to determine coverage. If your insurance does not pay for the test, you will be billed directly for $199.
Your Privacy is Important
We respect your privacy and appreciate the trust you have placed in us. Our lab is CAP-accredited and CLIA-certified and follows stringent medical privacy policies and practices. We adhere to the safe and secure storage of all personal health information in a way that is fully compliant with the federal government regulations of the Health Information Portability and Accountability Act (HIPAA).
Educational Resources for Treating Acute Pain
Request the AvertD Test
If you’re interested in the AvertD test, let your healthcare provider know. The test results can be used by you and your provider to decide whether opioid pain medications are an appropriate option for treating your acute pain. If they are not, you and your provider can explore other options.
Fill out our form with your provider’s contact information and we’ll contact them with information about the AvertD test. You can also download this letter, print it, and give it to your doctor at your next appointment.
1Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol Ther. 2009; 85(4):359–361. doi:10.1038/clpt.2009.6
2Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460
